Bookmark

Add to MyYahoo RSS

Actos, Pioglitazone News

News on Actos, Pioglitazone (generic) continually updated from thousands of sources around the net.

Saturday Jun 21 | CiteULike

Inflammatory genes in epicardial fat contiguous with coronary...

Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone.

Comment?

Related Topix: Medicine, Health, Diabetes, Metabolic Syndrome

Thu Jun 19, 2014

Freshnews

Legal-Bay Lawsuit Settlement Funding Reports $9 Billion in the first Actos (Pioglitazone) Settlement

Legal-Bay LLC, the Lawsuit Settlement Funding Company, disclosed today a new-implemented program involving lawsuit cash advances for clients facing complications due to risky Actos prescription drugs.

Comment?

Related Topix: Medicine, Biotech, Eli Lilly, Healthcare Industry, Diabetes, Health, Heart Failure

Tue Jun 17, 2014

BioMed Central

A systems biology approach to understand the pathophysiological...

Cardiac pathological hypertrophy is associated with a significantly increased risk of coronary heart disease and has been observed in diabetic patients treated with rosiglitazone whereas most published studies do not suggest a similar increase in risk of cardiovascular events in pioglitazone-treated diabetic subjects.

Comment?

Related Topix: Avandia, Rosiglitazone (generic), Medicine, Heart Disease, Health, Fasting

Mon Jun 16, 2014

Medical News Today

GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide)...

Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.

Comment?

Related Topix: Medicine, Diabetes, Health, Lantus, Insulin Glargine (generic)

BioSpace

Novo Nordisk A/S Combination Diabetes Drug IDegLira Effective After 1 Year Study

New One-year Data of IDegLira Shows Glucose-lowering Effect was Maintained for People With Type 2 Diabetes SAN FRANCISCO, Jun 14, 2014 -- SAN FRANCISCO, June 14, 2014 /PRNewswire/ - New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with ... (more)

Comment?

Related Topix: Medicine, Diabetes, Health, Insulin (generic), Humulin, Novolin, San Francisco County, CA, San Francisco, CA, Metformin (generic), Glucophage

Sat Jun 14, 2014

Applied Clinical Trials

New One-year Data of IDegLira Shows Glucose-lowering Effect was...

New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[ 1 ] Findings from the 26-week extension of the DUAL I clinical trial ... (more)

Comment?

Related Topix: Medicine, Insulin (generic), Humulin, Novolin, Diabetes, Health, Metformin (generic), Glucophage

Tue Jun 10, 2014

Postgraduate Medicine

Management of Patients Using Combination Therapy With Pioglitazone...

Current type 2 diabetes mellitus treatment involves progressive interventions from lifestyle changes to pharmacological therapies.

Comment?

Related Topix: Medicine

ETaiwanNews.com

Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to...

More than 40 presentations including posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company diabetes portfolio at the American Diabetes Association's 74 th Scientific Sessions R in San Francisco, 13-17 June.

Comment?

Related Topix: Medicine, Diabetes, Health, Biotech, Eli Lilly, Healthcare Industry, Lantus, Insulin Glargine (generic), Metformin (generic), Glucophage, Insulin (generic), Humulin, Novolin

•••
•••
•••
•••
•••
•••
•••